Results 81 to 90 of about 138,715 (220)

Understanding the Impact of the Sirtuin 1 (SIRT1) Gene on Age-related Macular Degeneration: A Comprehensive Study

open access: yesNigerian Postgraduate Medical Journal
Age-related macular degeneration (AMD) is a prevalent and incurable condition affecting the central retina and posing a significant risk to vision, particularly in individuals over the age of 60.
Saranya Velmurugan   +4 more
doaj   +1 more source

Age related macular degeneration [PDF]

open access: yesBMJ, 2003
Amresh, Chopdar   +2 more
openaire   +2 more sources

Complement inhibitors for age-related macular degeneration [PDF]

open access: yes, 2014
Given the relatively high prevalence of age-related macular degeneration (AMD) and the increased incidence of AMD as populations age, the results of trials of novel treatments are awaited with much anticipation.
Chakravarthy, Usha   +2 more
core   +1 more source

Nutrigenomics of Age-Related Macular Degeneration [PDF]

open access: yes, 2018
Lutein (L) and zeaxanthin (Z) are nutrients that reduce the risk of age-related macular degeneration (AMD). As micronutrients that selectively accumulate in the retina of the eye, L/Z can protect the macula from oxidative damage that contributes to AMD ...
Lin, Durpri
core   +1 more source

A Population-Based Ultra-Widefield Digital Image Grading Study for Age-Related Macular Degeneration-Like Lesions at the Peripheral Retina. [PDF]

open access: yes, 2015
Our understanding of the relevance of peripheral retinal abnormalities to disease in general and in age-related macular degeneration (AMD) in particular is limited by the lack of detailed peripheral imaging studies.
Bird, AC   +6 more
core   +1 more source

QM107, a novel CD148 (RTP Type J) activating peptide therapy for treating neovascular age-related macular degeneration. [PDF]

open access: yes
BACKGROUND AND PURPOSE: Angiogenesis is a pathological component of neovascular age-related macular degeneration. Current therapies, although successful, are prone to high levels of patient non-response and a loss of efficacy over time, indicating the ...
Arokiasamy, S   +11 more
core   +1 more source

Home - About - Disclaimer - Privacy